๋ํ๋๋กํํค์คํ ๋กค
**๋ํ๋๋กํํค์คํ ๋กค(DHT)**์ ํฉ์ฑ ์ง์ฉ์ฑ **๋นํ๋ฏผ D ์ ์ฌ์ฒด**๋ก, ์์ํ์์๋ ์ฃผ๋ก ๋ถ๊ฐ์์ ๊ธฐ๋ฅ ์ ํ์ฆ์ด๋ ์ค์ฆ ์ ์ฅ ์งํ์ ์๋ฐํ๋ ๊ณ ์นผ์ํ์ฆ์ ๊ด๋ฆฌํ๋ ๋ฐ ์ฌ์ฉ๋ฉ๋๋ค. ์ญ์ฌ์ ์ผ๋ก ์ค์ํ ์ฝ๋ฌผ์ด์ง๋ง, ์์ ์ ๊ณต๊ธ ๋ฌธ์ ์ ์นผ์ํธ๋ฆฌ์ฌ์ ๋ ์ ๋ฆฌํ ์ฝ๋ํ์ ํน์ฑ(์์ฉ ์์์ด ๋น ๋ฅด๊ณ ์์ฉ ์๊ฐ์ด ์งง์ ์ฐ๋ฐ์ ์ธ ๊ณ ์นผ์ํ์ฆ ๊ด๋ฆฌ๊ฐ ๋ ์ฉ์ดํจ)์ผ๋ก ์ธํด ์์์ ์ฌ์ฉ์ ๋๋ถ๋ถ **์นผ์ํธ๋ฆฌ์ฌ**๋ก ๋์ฒด๋์์ต๋๋ค. ์ฃผ์ ์์ ํฌ์ธํธ: * **์์ฉ ์์**: ์๋ฅด๊ณ ์นผ์ํ๋กค(๋นํ๋ฏผ D2)๋ณด๋ค ๋น ๋ฅด์ง๋ง ์นผ์ํธ๋ฆฌ์ฌ๋ณด๋ค๋ ๋๋ฆฝ๋๋ค. * **์ ์ฅ ํ์ฑํ ์ฐํ**: ์ฝ๋ ์นผ์ํ๋กค๊ณผ ๋ฌ๋ฆฌ DHT๋ ํ์ฑํ๋๊ธฐ ์ํด ์ ์ฅ์ 1-์ํ-์์ฐํํจ์๋ฅผ ํ์๋ก ํ์ง ์์ผ๋ฏ๋ก ์ค์ฆ ์ ๋ถ์ ํ์์๊ฒ ํจ๊ณผ์ ์ ๋๋ค. * **๋ ์ฑ ์ํ**: ์ฝํจ๊ฐ ์ฌ๋ผ์ง๋ ๋ฐ 1~3์ฃผ๊ฐ ๊ฑธ๋ฆด ์ ์์ผ๋ฏ๋ก ์์ธ์ฑ ๊ณ ์นผ์ํ์ฆ์ ์ํ์ด ํฌ๋ฉฐ ์ฒ ์ ํ ๋ชจ๋ํฐ๋ง์ด ํ์ํฉ๋๋ค.
์์ฉ ๊ธฐ์ : **Dihydrotachysterol** acts as a synthetic analog of 1,25-dihydroxyvitamin D. Its mechanism of action involves several key steps: * **Hepatic Activation**: DHT is absorbed from the GI tract and transported to the liver, where it undergoes hydroxylation by **hepatic 25-hydroxylase** โ **25-hydroxydihydrotachysterol** (the active metabolite). * **Receptor Binding**: The active metabolite binds to **Vitamin D Receptors (VDR)** in target tissues (primarily intestine, bone, and kidneys). * **Calcium Homeostasis**: * **Intestine**: Stimulates the synthesis of calcium-binding proteins (e.g., calbindin) โ significantly enhances dietary calcium and phosphorus absorption. * **Bone**: Works synergistically with parathyroid hormone (PTH) to promote the accretion and resorption of minerals, mobilizing calcium into the extracellular fluid. * **Kidneys**: Promotes the reabsorption of calcium by the renal tubules. > **Clinical Pearl**: Because the active form of DHT is structurally similar to 1,25-dihydroxyvitamin D, it effectively bypasses the need for **renal 1-alpha-hydroxylase**, an enzyme often deficient in chronic kidney disease.
๋๋ฌผ ์ข ๋ณ ์ฉ๋
- Hypocalcemia secondary to hypoparathyroidism ยท Initially give 0.03 mg/kg PO for several days or until effect is demonstrated, then give 0.02 mg/kg for 2 days, then 0.01 mg/kg per day. ยท PO ยท q24h ยท Pet should remain hospitalized until serum calcium concentration remains stable between 8-9.5 mg/dL. Recheck serum calcium on a weekly basis during early stages of treatment; recheck every 2-3 months long-term. Some dogs and cats that appear to be resistant to treatment on tablets or capsules may respond to the liquid form.
- Chronic hypocalcemia with oral calcium tx ยท Initially: 0.02-0.03 mg/kg/day PO. Maintenance: 0.01-0.02 mg/kg PO q24-48h. ยท PO ยท q24-48h
- Hypocalcemia secondary to hypoparathyroidism ยท Initially give 0.03 mg/kg PO for several days or until effect is demonstrated, then give 0.02 mg/kg for 2 days, then 0.01 mg/kg per day. ยท PO ยท q24h ยท Pet should remain hospitalized until serum calcium concentration remains stable between 8-9.5 mg/dL. Recheck serum calcium on a weekly basis during early stages of treatment; recheck every 2-3 months long-term. Some dogs and cats that appear to be resistant to treatment on tablets or capsules may respond to the liquid form.
์ฉ๋์ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์ฐธ๊ณ ์๋ฃ์ ๋๋ค. ํญ์ ์ต์ ๋ผ๋ฒจ๊ณผ ๊ฐ๋ณ ํ์์ ๋ํด ํ์ธํ์ญ์์ค.
ํฌ์ฌ ๊ฒฝ๋ก
๊ธ๊ธฐ
- Pre-existing hypercalcemia
- Vitamin D toxicity
- Malabsorption syndromes
- Abnormal sensitivity to the effects of vitamin D
์ด์๋ฐ์
- Hypercalcemia (manifesting as polydipsia, polyuria, anorexia, vomiting, lethargy)
- Nephrocalcinosis (soft tissue mineralization)
- Hyperphosphatemia
์ฝ๋ฌผ ์ํธ์์ฉ
- Calcium-containing phosphorus binding agents (e.g., calcium carbonate) ยท Use with vitamin D analogs may induce severe hypercalcemia.
- Corticosteroids ยท Can nullify the calcium-elevating effects of vitamin D analogs.
- Digoxin ยท Patients are highly sensitive to the arrhythmogenic effects of hypercalcemia; intensified monitoring is required.
- Verapamil ยท Patients are sensitive to the effects of hypercalcemia; intensified monitoring is required.
- Mineral oil ยท May reduce the amount of DHT absorbed from the GI tract.
- Sucralfate ยท May reduce the amount of DHT absorbed from the GI tract.
- Cholestyramine ยท May reduce the amount of DHT absorbed from the GI tract.
- Phenytoin ยท May induce hepatic enzyme systems and increase the metabolism of Vitamin D analogs, thus decreasing their activity.
- Barbiturates ยท May induce hepatic enzyme systems and increase the metabolism of Vitamin D analogs, thus decreasing their activity.
- Primidone ยท May induce hepatic enzyme systems and increase the metabolism of Vitamin D analogs, thus decreasing their activity.
- Thiazide diuretics ยท May cause hypercalcemia when given in conjunction with Vitamin D analogs.
๋ชจ๋ํฐ๋ง
- Serum calcium levels (closely/twice daily during initial treatment; at least 2-4 times yearly during maintenance)
- Serum phosphorus levels (particularly in renal failure patients)
- Calcium-phosphorus product (Ca x P)
๊ณผ์ฉ๋
### Acute Toxicity Acute ingestions should be managed using established protocols for GI decontamination. **Orally administered mineral oil** may reduce absorption and enhance fecal elimination. ### Chronic Toxicity (Hypercalcemia) Hypercalcemia secondary to chronic dosing is a serious complication. 1. **Discontinue Therapy**: Immediately stop DHT and any exogenous calcium supplementation. 2. **Severe Hypercalcemia Management**: Administer **furosemide**, **calcium-free IV fluids** (e.g., 0.9% normal saline) to promote diuresis, urine acidification, and **corticosteroids** (which decrease intestinal calcium absorption and increase renal excretion). 3. **Monitoring**: Because of the long duration of action of DHT (usually one week and potentially up to 3 weeks), hypercalcemia may persist for an extended period. 4. **Re-initiation**: Restart DHT/calcium therapy at a reduced dosage with diligent monitoring only when serum calcium levels return to the normal range.
VetSheet ์ฝ๋ฌผ ๋ ํผ๋ฐ์ค๋ ๋ฉดํ ์์ ์ ๋ฌธ๊ฐ๋ฅผ ์ํ ์์ ์์ฌ๊ฒฐ์ ๋ณด์กฐ ๋๊ตฌ์ด๋ฉฐ, ์ ๋ฌธ์ ํ๋จ์ด๋ ์ ์กฐ์ฌ์ ์ต์ ๋ผ๋ฒจ์ ๋์ ํ์ง ์์ต๋๋ค.